---
layout: default
title: "Cross-Enhanced Multimodal Fusion of Eye-Tracking and Facial Features for Alzheimer's Disease Diagnosis"
---

# Cross-Enhanced Multimodal Fusion of Eye-Tracking and Facial Features for Alzheimer's Disease Diagnosis

<div class="paper-toolbar">
  <a href="https://arxiv.org/abs/2510.24777" class="toolbar-btn" target="_blank">üìÑ arXiv: 2510.24777v1</a>
  <a href="https://arxiv.org/pdf/2510.24777.pdf" class="toolbar-btn" target="_blank">üì• PDF</a>
  <button class="toolbar-btn favorite-btn" data-arxiv-id="2510.24777v1" data-paper-url="__CURRENT_PAGE__" onclick="toggleFavorite(this, '2510.24777v1', 'Cross-Enhanced Multimodal Fusion of Eye-Tracking and Facial Features for Alzheimer\'s Disease Diagnosis')" title="Ê∑ªÂä†Âà∞Êî∂ËóèÂ§π">‚òÜ Êî∂Ëóè</button>
  <button class="toolbar-btn" onclick="copyLinkToClipboard(this)">üîó ÂàÜ‰∫´</button>
</div>


**‰ΩúËÄÖ**: Yujie Nie, Jianzhang Ni, Yonglong Ye, Yuan-Ting Zhang, Yun Kwok Wing, Xiangqing Xu, Xin Ma, Lizhou Fan

**ÂàÜÁ±ª**: cs.CV, cs.AI, eess.IV

**ÂèëÂ∏ÉÊó•Êúü**: 2025-10-25

**Â§áÊ≥®**: 35 pages, 8 figures, and 7 tables

---

## üí° ‰∏ÄÂè•ËØùË¶ÅÁÇπ

**ÊèêÂá∫‰∏ÄÁßç‰∫§ÂèâÂ¢ûÂº∫ÁöÑÂ§öÊ®°ÊÄÅËûçÂêàÊ°ÜÊû∂ÔºåÁî®‰∫éÁúºÂä®ËøΩË∏™ÂíåÈù¢ÈÉ®ÁâπÂæÅÁöÑÈòøÂ∞îËå®Êµ∑ÈªòÁóÖËØäÊñ≠„ÄÇ**

üéØ **ÂåπÈÖçÈ¢ÜÂüü**: **ÊîØÊü±‰∫åÔºöRLÁÆóÊ≥ï‰∏éÊû∂ÊûÑ (RL & Architecture)** **ÊîØÊü±‰πùÔºöÂÖ∑Ë∫´Â§ßÊ®°Âûã (Embodied Foundation Models)**

**ÂÖ≥ÈîÆËØç**: `ÈòøÂ∞îËå®Êµ∑ÈªòÁóÖËØäÊñ≠` `Â§öÊ®°ÊÄÅËûçÂêà` `ÁúºÂä®ËøΩË∏™` `Èù¢ÈÉ®ÁâπÂæÅ` `‰∫§ÂèâÊ≥®ÊÑèÂäõ` `ÊñπÂêëÊÑüÁü•Âç∑ÁßØ`

## üìã Ê†∏ÂøÉË¶ÅÁÇπ

1. Áé∞ÊúâÊñπÊ≥ïÂú®ÈòøÂ∞îËå®Êµ∑ÈªòÁóÖËæÖÂä©ËØäÊñ≠‰∏≠ÔºåËæÉÂ∞ëÊé¢Á¥¢ÁúºÂä®ËøΩË∏™ÂíåÈù¢ÈÉ®ÁâπÂæÅÁöÑËÅîÂêàÈõÜÊàêÔºåÈôêÂà∂‰∫ÜËØäÊñ≠ÁöÑÂáÜÁ°ÆÊÄß„ÄÇ
2. ÊèêÂá∫‰∏ÄÁßç‰∫§ÂèâÂ¢ûÂº∫ÁöÑÂ§öÊ®°ÊÄÅËûçÂêàÊ°ÜÊû∂ÔºåÈÄöËøá‰∫§ÂèâÊ≥®ÊÑèÂäõÂíåÊñπÂêëÊÑüÁü•Âç∑ÁßØÔºåËá™ÈÄÇÂ∫îÂú∞Â≠¶‰π†Âà§Âà´ÊÄßË°®ÂæÅ„ÄÇ
3. Âú®Ëá™Âª∫ÁöÑÂ§öÊ®°ÊÄÅÊï∞ÊçÆÈõÜ‰∏äÔºåËØ•Ê°ÜÊû∂Ë∂ÖË∂ä‰∫Ü‰º†ÁªüÊñπÊ≥ïÔºåÂÆûÁé∞‰∫Ü95.11%ÁöÑÂàÜÁ±ªÂáÜÁ°ÆÁéáÔºåÊèêÂçá‰∫ÜËØäÊñ≠ÊÄßËÉΩ„ÄÇ

## üìù ÊëòË¶ÅÔºà‰∏≠ÊñáÔºâ

Êú¨Á†îÁ©∂ÊèêÂá∫‰∫Ü‰∏ÄÁßçÂ§öÊ®°ÊÄÅ‰∫§ÂèâÂ¢ûÂº∫ËûçÂêàÊ°ÜÊû∂ÔºåÊó®Âú®ÂçèÂêåÂà©Áî®ÁúºÂä®ËøΩË∏™ÂíåÈù¢ÈÉ®ÁâπÂæÅËøõË°åÈòøÂ∞îËå®Êµ∑ÈªòÁóÖÔºàADÔºâÊ£ÄÊµãÔºå‰ªéËÄåÂÆûÁé∞ÂèäÊó∂Âπ≤È¢ÑÂπ∂Âª∂ÁºìÁñæÁóÖËøõÂ±ï„ÄÇËØ•Ê°ÜÊû∂ÂåÖÂê´‰∏§‰∏™ÂÖ≥ÈîÆÊ®°ÂùóÔºö(a) ‰∫§ÂèâÂ¢ûÂº∫ËûçÂêàÊ≥®ÊÑèÂäõÊ®°ÂùóÔºàCEFAMÔºâÔºåÈÄöËøá‰∫§ÂèâÊ≥®ÊÑèÂäõÂíåÂÖ®Â±ÄÂ¢ûÂº∫Êù•Âª∫Ê®°Ê®°ÊÄÅÈó¥‰∫§‰∫íÔºõ(b) ÊñπÂêëÊÑüÁü•Âç∑ÁßØÊ®°ÂùóÔºàDACMÔºâÔºåÈÄöËøáÊ∞¥Âπ≥-ÂûÇÁõ¥ÊÑüÂèóÈáéÊçïËé∑ÁªÜÁ≤íÂ∫¶ÁöÑÊñπÂêëÊÄßÈù¢ÈÉ®ÁâπÂæÅ„ÄÇËøô‰∫õÊ®°ÂùóÂÖ±ÂêåÂÆûÁé∞‰∫ÜËá™ÈÄÇÂ∫îÂíåÂà§Âà´ÊÄßÁöÑÂ§öÊ®°ÊÄÅË°®ÂæÅÂ≠¶‰π†„ÄÇ‰∏∫‰∫ÜÊîØÊåÅËøôÈ°πÂ∑•‰ΩúÔºåÊàë‰ª¨ÊûÑÂª∫‰∫Ü‰∏Ä‰∏™ÂêåÊ≠•ÁöÑÂ§öÊ®°ÊÄÅÊï∞ÊçÆÈõÜÔºåÂåÖÊã¨25ÂêçADÊÇ£ËÄÖÂíå25ÂêçÂÅ•Â∫∑ÂØπÁÖßËÄÖÔºàHCÔºâÔºåÈÄöËøáÂú®ËßÜËßâËÆ∞ÂøÜÊêúÁ¥¢ËåÉÂºè‰∏≠ËÆ∞ÂΩïÂØπÈΩêÁöÑÈù¢ÈÉ®ËßÜÈ¢ëÂíåÁúºÂä®ËøΩË∏™Â∫èÂàóÔºå‰∏∫ËØÑ‰º∞ÈõÜÊàêÁ≠ñÁï•Êèê‰æõ‰∫Ü‰∏Ä‰∏™ÁîüÊÄÅÊúâÊïàÁöÑËµÑÊ∫ê„ÄÇÂ§ßÈáèÂÆûÈ™åË°®ÊòéÔºåÊàë‰ª¨ÁöÑÊ°ÜÊû∂‰ºò‰∫é‰º†ÁªüÁöÑÂêéÊúüËûçÂêàÂíåÁâπÂæÅËøûÊé•ÊñπÊ≥ïÔºåÂú®Âå∫ÂàÜADÂíåHCÊñπÈù¢ÂÆûÁé∞‰∫Ü95.11%ÁöÑÂàÜÁ±ªÂáÜÁ°ÆÁéáÔºåÁ™ÅÂá∫‰∫ÜÈÄöËøáÊòæÂºèÂª∫Ê®°Ê®°ÊÄÅÈó¥‰æùËµñÊÄßÂíåÊ®°ÊÄÅÁâπÂÆöË¥°ÁåÆÊâÄÂÆûÁé∞ÁöÑÂçìË∂äÈ≤ÅÊ£íÊÄßÂíåËØäÊñ≠ÊÄßËÉΩ„ÄÇ

## üî¨ ÊñπÊ≥ïËØ¶Ëß£

**ÈóÆÈ¢òÂÆö‰πâ**ÔºöÈòøÂ∞îËå®Êµ∑ÈªòÁóÖÔºàADÔºâÁöÑÊó©ÊúüËØäÊñ≠ÂØπ‰∫éÂèäÊó∂Âπ≤È¢ÑËá≥ÂÖ≥ÈáçË¶Å„ÄÇÁé∞ÊúâÁöÑËØäÊñ≠ÊñπÊ≥ïÔºåÁâπÂà´ÊòØÂü∫‰∫éÂçï‰∏ÄÊ®°ÊÄÅÁöÑÊñπÊ≥ïÔºåÂèØËÉΩÊó†Ê≥ïÂÖÖÂàÜÊçïÊçâADÊÇ£ËÄÖÂú®ËÆ§Áü•ÂíåË°å‰∏∫‰∏äÁöÑÂ§çÊùÇÂèòÂåñ„ÄÇËôΩÁÑ∂ÁúºÂä®ËøΩË∏™ÂíåÈù¢ÈÉ®ÁâπÂæÅÊòØÈáçË¶ÅÁöÑËÆ§Áü•ÂäüËÉΩÊåáÊ†áÔºå‰ΩÜÂæàÂ∞ëÊúâÁ†îÁ©∂Êé¢Á¥¢Â¶Ç‰ΩïÊúâÊïàÂú∞Â∞ÜÂÆÉ‰ª¨ËûçÂêàÁî®‰∫éADËØäÊñ≠„ÄÇ‰º†ÁªüÁöÑÂêéÊúüËûçÂêàÂíåÁâπÂæÅËøûÊé•ÊñπÊ≥ïÊó†Ê≥ïÂÖÖÂàÜÂà©Áî®Ê®°ÊÄÅÈó¥ÁöÑ‰∫íË°•‰ø°ÊÅØÂíå‰æùËµñÂÖ≥Á≥ªÔºåÂØºËá¥ËØäÊñ≠ÊÄßËÉΩÂèóÈôê„ÄÇ

**Ê†∏ÂøÉÊÄùË∑Ø**ÔºöÊú¨Á†îÁ©∂ÁöÑÊ†∏ÂøÉÊÄùË∑ØÊòØËÆæËÆ°‰∏Ä‰∏™ËÉΩÂ§üÊòæÂºèÂª∫Ê®°ÁúºÂä®ËøΩË∏™ÂíåÈù¢ÈÉ®ÁâπÂæÅ‰πãÈó¥‰∫§‰∫íÁöÑÊ°ÜÊû∂Ôºå‰ªéËÄåÊèêÂèñÊõ¥ÂÖ∑Âà§Âà´ÊÄßÁöÑÂ§öÊ®°ÊÄÅË°®ÂæÅ„ÄÇÈÄöËøáÂºïÂÖ•‰∫§ÂèâÊ≥®ÊÑèÂäõÊú∫Âà∂ÔºåÊ°ÜÊû∂ÂèØ‰ª•Ëá™ÈÄÇÂ∫îÂú∞Â≠¶‰π†‰∏çÂêåÊ®°ÊÄÅÁöÑÊùÉÈáçÔºåÂπ∂ÊçïÊçâÂÆÉ‰ª¨‰πãÈó¥ÁöÑ‰æùËµñÂÖ≥Á≥ª„ÄÇÂêåÊó∂ÔºåÂà©Áî®ÊñπÂêëÊÑüÁü•Âç∑ÁßØÊ®°ÂùóÊèêÂèñÁªÜÁ≤íÂ∫¶ÁöÑÈù¢ÈÉ®ÁâπÂæÅÔºåÂ¢ûÂº∫Ê®°ÂûãÂØπADÁõ∏ÂÖ≥Èù¢ÈÉ®ÂèòÂåñÁöÑÊïèÊÑüÊÄß„ÄÇ

**ÊäÄÊúØÊ°ÜÊû∂**ÔºöËØ•Ê°ÜÊû∂‰∏ªË¶ÅÂåÖÂê´‰∏§‰∏™ÂÖ≥ÈîÆÊ®°ÂùóÔºö‰∫§ÂèâÂ¢ûÂº∫ËûçÂêàÊ≥®ÊÑèÂäõÊ®°ÂùóÔºàCEFAMÔºâÂíåÊñπÂêëÊÑüÁü•Âç∑ÁßØÊ®°ÂùóÔºàDACMÔºâ„ÄÇÈ¶ñÂÖàÔºåÂàÜÂà´ÊèêÂèñÁúºÂä®ËøΩË∏™ÂíåÈù¢ÈÉ®ÁâπÂæÅ„ÄÇÁÑ∂ÂêéÔºåCEFAMÊ®°ÂùóÂà©Áî®‰∫§ÂèâÊ≥®ÊÑèÂäõÊú∫Âà∂Âª∫Ê®°Ê®°ÊÄÅÈó¥ÁöÑ‰∫§‰∫íÔºåÂπ∂ÈÄöËøáÂÖ®Â±ÄÂ¢ûÂº∫Êù•ÊèêÂçáÁâπÂæÅÁöÑË°®ËææËÉΩÂäõ„ÄÇDACMÊ®°ÂùóÂàôÈÄöËøáÊ∞¥Âπ≥ÂíåÂûÇÁõ¥ÊñπÂêëÁöÑÂç∑ÁßØÊ†∏ÊèêÂèñÁªÜÁ≤íÂ∫¶ÁöÑÊñπÂêëÊÄßÈù¢ÈÉ®ÁâπÂæÅ„ÄÇÊúÄÂêéÔºåÂ∞Ü‰∏§‰∏™Ê®°ÂùóÁöÑËæìÂá∫ËøõË°åËûçÂêàÔºåÂπ∂‰ΩøÁî®ÂàÜÁ±ªÂô®ËøõË°åADËØäÊñ≠„ÄÇ

**ÂÖ≥ÈîÆÂàõÊñ∞**ÔºöËØ•Á†îÁ©∂ÁöÑÂÖ≥ÈîÆÂàõÊñ∞Âú®‰∫éÊèêÂá∫‰∫ÜCEFAMÂíåDACM‰∏§‰∏™Ê®°ÂùóÔºå‰ª•ÂèäÂ∞ÜÂÆÉ‰ª¨ÈõÜÊàêÂà∞‰∏Ä‰∏™Áªü‰∏ÄÁöÑÊ°ÜÊû∂‰∏≠„ÄÇCEFAMÈÄöËøá‰∫§ÂèâÊ≥®ÊÑèÂäõÊú∫Âà∂ÊòæÂºèÂú∞Âª∫Ê®°‰∫ÜÊ®°ÊÄÅÈó¥ÁöÑ‰∫§‰∫íÔºåÂÖãÊúç‰∫Ü‰º†ÁªüËûçÂêàÊñπÊ≥ïÂøΩÁï•Ê®°ÊÄÅÈó¥‰æùËµñÂÖ≥Á≥ªÁöÑÁº∫ÁÇπ„ÄÇDACMÂàôÈÄöËøáÊñπÂêëÊÑüÁü•Âç∑ÁßØÊèêÂèñ‰∫ÜÊõ¥ÂÖ∑Âà§Âà´ÊÄßÁöÑÈù¢ÈÉ®ÁâπÂæÅÔºåÂ¢ûÂº∫‰∫ÜÊ®°ÂûãÂØπADÁõ∏ÂÖ≥Èù¢ÈÉ®ÂèòÂåñÁöÑÊïèÊÑüÊÄß„ÄÇ

**ÂÖ≥ÈîÆËÆæËÆ°**ÔºöCEFAMÊ®°Âùó‰ΩøÁî®Â§öÂ§¥Ê≥®ÊÑèÂäõÊú∫Âà∂Êù•ÂÆûÁé∞‰∫§ÂèâÊ≥®ÊÑèÂäõÔºåÂÖÅËÆ∏Ê®°Âûã‰ªé‰∏çÂêåÁöÑËßíÂ∫¶ÂÖ≥Ê≥®‰∏çÂêåÊ®°ÊÄÅÁöÑ‰ø°ÊÅØ„ÄÇÂÖ®Â±ÄÂ¢ûÂº∫ÈááÁî®ÊÆãÂ∑ÆËøûÊé•ÁöÑÊñπÂºèÔºåÈÅøÂÖç‰∫ÜÊ¢ØÂ∫¶Ê∂àÂ§±ÈóÆÈ¢ò„ÄÇDACMÊ®°Âùó‰ΩøÁî®‰∏§‰∏™ÊñπÂêëÔºàÊ∞¥Âπ≥ÂíåÂûÇÁõ¥ÔºâÁöÑÂç∑ÁßØÊ†∏ÔºåÂàÜÂà´ÊèêÂèñÊ∞¥Âπ≥ÂíåÂûÇÁõ¥ÊñπÂêëÁöÑÊ¢ØÂ∫¶‰ø°ÊÅØ„ÄÇÊçüÂ§±ÂáΩÊï∞ÈááÁî®‰∫§ÂèâÁÜµÊçüÂ§±ÂáΩÊï∞ÔºåÁî®‰∫éËÆ≠ÁªÉÂàÜÁ±ªÂô®„ÄÇ

## üìä ÂÆûÈ™å‰∫ÆÁÇπ

ÂÆûÈ™åÁªìÊûúË°®ÊòéÔºåËØ•Ê°ÜÊû∂Âú®Ëá™Âª∫ÁöÑÂ§öÊ®°ÊÄÅÊï∞ÊçÆÈõÜ‰∏äÂÆûÁé∞‰∫Ü95.11%ÁöÑÂàÜÁ±ªÂáÜÁ°ÆÁéáÔºåÊòæËëó‰ºò‰∫é‰º†ÁªüÁöÑÂêéÊúüËûçÂêàÂíåÁâπÂæÅËøûÊé•ÊñπÊ≥ï„ÄÇ‰∏é‰ªÖ‰ΩøÁî®ÁúºÂä®ËøΩË∏™ÊàñÈù¢ÈÉ®ÁâπÂæÅÁöÑÂçïÊ®°ÊÄÅÊñπÊ≥ïÁõ∏ÊØîÔºåËØ•Ê°ÜÊû∂ÁöÑÊÄßËÉΩ‰πüÂæóÂà∞‰∫ÜÊòæËëóÊèêÂçáÔºåÈ™åËØÅ‰∫ÜÂ§öÊ®°ÊÄÅËûçÂêàÁöÑÊúâÊïàÊÄß„ÄÇÊ∂àËûçÂÆûÈ™åËøõ‰∏ÄÊ≠•ËØÅÊòé‰∫ÜCEFAMÂíåDACMÊ®°ÂùóÁöÑÊúâÊïàÊÄß„ÄÇ

## üéØ Â∫îÁî®Âú∫ÊôØ

ËØ•Á†îÁ©∂ÊàêÊûúÂèØÂ∫îÁî®‰∫éÈòøÂ∞îËå®Êµ∑ÈªòÁóÖÁöÑÊó©ÊúüËæÖÂä©ËØäÊñ≠ÔºåÂ∏ÆÂä©ÂåªÁîüÊõ¥ÂáÜÁ°ÆÂú∞ËØÜÂà´È´òÈ£éÈô©‰∫∫Áæ§Ôºå‰ªéËÄåËøõË°åÊó©ÊúüÂπ≤È¢ÑÂíåÁÆ°ÁêÜ„ÄÇÊ≠§Â§ñÔºåËØ•Â§öÊ®°ÊÄÅËûçÂêàÊ°ÜÊû∂‰πüÂèØÊâ©Â±ïÂà∞ÂÖ∂‰ªñÁ•ûÁªèÈÄÄË°åÊÄßÁñæÁóÖÁöÑËØäÊñ≠ÔºåÂÖ∑ÊúâÂπøÈòîÁöÑÂ∫îÁî®ÂâçÊôØ„ÄÇÊú™Êù•ÔºåÁªìÂêàÂèØÁ©øÊà¥ËÆæÂ§áÔºåÊúâÊúõÂÆûÁé∞ADÁöÑËøúÁ®ãÁõëÊµãÂíå‰∏™ÊÄßÂåñÁÆ°ÁêÜ„ÄÇ

## üìÑ ÊëòË¶ÅÔºàÂéüÊñáÔºâ

> Accurate diagnosis of Alzheimer's disease (AD) is essential for enabling timely intervention and slowing disease progression. Multimodal diagnostic approaches offer considerable promise by integrating complementary information across behavioral and perceptual domains. Eye-tracking and facial features, in particular, are important indicators of cognitive function, reflecting attentional distribution and neurocognitive state. However, few studies have explored their joint integration for auxiliary AD diagnosis. In this study, we propose a multimodal cross-enhanced fusion framework that synergistically leverages eye-tracking and facial features for AD detection. The framework incorporates two key modules: (a) a Cross-Enhanced Fusion Attention Module (CEFAM), which models inter-modal interactions through cross-attention and global enhancement, and (b) a Direction-Aware Convolution Module (DACM), which captures fine-grained directional facial features via horizontal-vertical receptive fields. Together, these modules enable adaptive and discriminative multimodal representation learning. To support this work, we constructed a synchronized multimodal dataset, including 25 patients with AD and 25 healthy controls (HC), by recording aligned facial video and eye-tracking sequences during a visual memory-search paradigm, providing an ecologically valid resource for evaluating integration strategies. Extensive experiments on this dataset demonstrate that our framework outperforms traditional late fusion and feature concatenation methods, achieving a classification accuracy of 95.11% in distinguishing AD from HC, highlighting superior robustness and diagnostic performance by explicitly modeling inter-modal dependencies and modality-specific contributions.

